Cargando…
The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
BACKGROUND AND PURPOSE: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different do...
Autores principales: | Sun, Dantong, Hou, Helei, Zhang, Chuantao, Zhang, Xiaochun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178936/ https://www.ncbi.nlm.nih.gov/pubmed/30323627 http://dx.doi.org/10.2147/OTT.S176429 |
Ejemplares similares
-
Progress in the treatment of solid tumors with apatinib: a systematic review
por: Zhao, Deze, et al.
Publicado: (2018) -
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
por: Hou, Helei, et al.
Publicado: (2019) -
The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
por: Hou, Helei, et al.
Publicado: (2019) -
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021) -
Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)